Kyprolis® treatment combination recommended for use across Europe

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive recommendation for the use of Kyprolis (carfilzomib) in combination with Revlimid® (lenalidomide) and dexamethasone as a treatment for relapsed myeloma patients who have received at least one previous line of treatment. The recommendation was based on results of the…

Details